Search Results - Ani Sarkis Balmanoukian

Refine Results
  1. 1
    The Association Between Treatment-Related Lymphopenia and Survival in Newly Diagnosed Patients with Resected Adenocarcinoma of the Pancreas

    The Association Between Treatment-Related Lymphopenia and Survival in Newly Diagnosed Patients with Resected Adenocarcinoma of the Pancreas by Ani Sarkis Balmanoukian, Xiaobu Ye, Joseph M. Herman, Daniel A. Laheru, Stuart A. Grossman

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Sustained CD4<sup>+</sup>T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide

    Sustained CD4<sup>+</sup>T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide by Susannah G. Ellsworth, Ani Sarkis Balmanoukian, Ferdynand Kos, Christopher J. Nirschl, Thomas R. Nirschl, Stuart A. Grossman, Leo Luznik, Charles G. Drake

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors

    Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors by Stuart A. Grossman, Susannah G. Ellsworth, Jian L. Campian, Aaron T. Wild, Joseph M. Herman, Dan Laheru, Malcolm V. Brock, Ani Sarkis Balmanoukian, Xiaobu Ye

    Published 2015
    Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC)

    Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC) by J. R. Infante, Fadi Braiteh, Leisha A. Emens, Ani Sarkis Balmanoukian, Ana Oaknin, Y. Wang, B. Liu, Luciana Molinero, Marcella Fassò, Carol O’Hear, Michael S. Gordon

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

    Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study by Scott Antonia, Sarah B. Goldberg, Ani Sarkis Balmanoukian, Jamie E. Chaft, Rachel E. Sanborn, Ashok Gupta, Rajesh Narwal, Keith E. Steele, Yu Gu, Joyson Karakunnel, Naiyer A. Rizvi

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers

    Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers by Tara C. Gangadhar, Omid Hamid, David C. Smith, Todd M. Bauer, Jeffrey S. Wasser, Jason J. Luke, Ani Sarkis Balmanoukian, David R. Kaufman, Yufan Zhao, Janet Maleski, Lance Leopold, Thomas F. Gajewski

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial

    Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial by A. Dimitrios Colevas, Rastislav Bahleda, Fadi Braiteh, Ani Sarkis Balmanoukian, Irene Braña, Nicole G. Chau, Indrani Sarkar, Luciana Molinero, William Grossman, Fairooz F. Kabbinavar, Marcella Fassò, Carol O’Hear, John D. Powderly

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Epacadostat plus pembrolizumab in patients with advanced melanoma: Phase 1 and 2 efficacy and safety results from ECHO-202/KEYNOTE-037

    Epacadostat plus pembrolizumab in patients with advanced melanoma: Phase 1 and 2 efficacy and safety results from ECHO-202/KEYNOTE-037 by Omid Hamid, Thomas F. Gajewski, Arthur E. Frankel, Todd M. Bauer, Anthony J. Olszanski, Jason J. Luke, Ani Sarkis Balmanoukian, Emmett V. Schmidt, Brian J. Sharkey, Janet Maleski, Michelle Jones, Tara C. Gangadhar

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037

    Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037 by Tara C. Gangadhar, Omid Hamid, David C. Smith, Todd M. Bauer, Jeffrey S. Wasser, Anthony J. Olszanski, Jason J. Luke, Ani Sarkis Balmanoukian, David R. Kaufman, Yufan Zhao, Janet Maleski, Michelle Jones, L. Leopold, Thomas F. Gajewski

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)

    Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037) by Tara C. Mitchell, Omid Hamid, David C. Smith, Todd M. Bauer, Jeffrey S. Wasser, Anthony J. Olszanski, Jason J. Luke, Ani Sarkis Balmanoukian, Emmett V. Schmidt, Yufan Zhao, Xiaohua Gong, Janet Maleski, Lance Leopold, Thomas F. Gajewski

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors

    A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors by David S. Hong, Drew Rasco, Michael H. Veeder, Jason J. Luke, Jason C. Chandler, Ani Sarkis Balmanoukian, Thomas J. George, Pamela N. Münster, Jordan Berlin, Martin Gutierrez, Alain C. Mita, Heather A. Wakelee, Selda Samakoglu, Shanhong Guan, Isaiah W. Dimery, Thorsten Graef, Erkut Borazanci

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors

    Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors by Ani Sarkis Balmanoukian, Jeffrey R. Infante, Raid Aljumaily, Aung Naing, Ashish V. Chintakuntlawar, Naiyer A. Rizvi, Helen J. Ross, Michael S. Gordon, Philip R. Mallinder, Nairouz Elgeioushi, Ignacio Ferreira González, Nathan Standifer, Jennifer Cann, Nicholas M. Durham, Shahram Rahimian, Rakesh Kumar, Crystal S. Denlinger

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

    Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study by Andrea B. Apolo, Jeffrey R. Infante, Ani Sarkis Balmanoukian, Manish R. Patel, Ding Wang, Karen Kelly, Anthony Mega, Carolyn D. Britten, Alain Ravaud, Alain C. Mita, Howard Safran, Thomas E. Stinchcombe, Marko Srdanov, Arnold B. Gelb, Michael Schlichting, Kevin M. Chin, James L. Gulley

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

    Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study by Edward B. Garon, Matthew D. Hellmann, Naiyer A. Rizvi, Enric Carcereny, Natasha B. Leighl, Myung‐Ju Ahn, Joseph P. Eder, Ani Sarkis Balmanoukian, Charu Aggarwal, Leora Horn, Amita Patnaik, Matthew A. Gubens, Suresh S. Ramalingam, Enriqueta Felip, Jonathan W. Goldman, Cathie Scalzo, Erin Jensen, Debra Kush, Rina Hui

    Published 2019
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Antitumor Activity of Pembrolizumab (Pembro; Mk-3475) and Correlation with Programmed Death Ligand 1 (Pd-L1) Expression in a Pooled Analysis of Patients (Pts) with Advanced Non–Small Cell Lung Carcinoma (Nsclc)

    Antitumor Activity of Pembrolizumab (Pembro; Mk-3475) and Correlation with Programmed Death Ligand 1 (Pd-L1) Expression in a Pooled Analysis of Patients (Pts) with Advanced Non–Sma... by Edward B. Garon, Leena Gandhi, Naiyer A. Rizvi, Rina Hui, Ani Sarkis Balmanoukian, Amita Patnaik, Joseph P. Eder, George Blumenshein, Charu Aggarwal, J.C. Soria, Myung‐Ju Ahn, Matthew A. Gubens, Suresh S. Ramalingam, Elizabeth A. Johnson, Hendrik‐Tobias Arkenau, Gregory M. Lubiniecki, J. Zhang, R. Rutledge, Kenneth Emancipator, Natasha B. Leighl

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    LBA O-9 Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer

    LBA O-9 Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer by Andrea J. Bullock, Joseph E. Grossman, Marwan Fakih, Heinz‐Josef Lenz, Michael S. Gordon, Kim Margolin, Breelyn A. Wilky, Daruka Mahadevan, Jonathan C. Trent, Bruno Bockorny, Justin C. Moser, Ani Sarkis Balmanoukian, Benjamin L. Schlechter, Waldo Ortuzar Feliu, Katherine Rosenthal, Bonnie Bullock, Justin Stebbing, James Godwin, Steven O’Day, Apostolia M. Tsimberidou, A. El-Khoueiry

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

    Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer by Edward B. Garon, Naiyer A. Rizvi, Rina Hui, Natasha B. Leighl, Ani Sarkis Balmanoukian, Joseph P. Eder, Amita Patnaik, Charu Aggarwal, Matthew A. Gubens, Leora Horn, Enric Carcereny, Myung‐Ju Ahn, Enriqueta Felip, Jong-Seok Lee, Matthew D. Hellmann, Omid Hamid, Jonathan W. Goldman, Jean‐Charles Soria, Marisa Dolled‐Filhart, Ruth Z. Rutledge, Jin Zhang, Jared Lunceford, Reshma Rangwala, Gregory M. Lubiniecki, Charlotte Roach, Kenneth Emancipator, Leena Gandhi

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial

    Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial by Andrea J. Bullock, Benjamin L. Schlechter, Marwan Fakih, Apostolia M. Tsimberidou, Joseph E. Grossman, Michael S. Gordon, Breelyn A. Wilky, Agustin Pimentel, Daruka Mahadevan, Ani Sarkis Balmanoukian, Rachel E. Sanborn, Gary K. Schwartz, Ghassan K. Abou‐Alfa, Neil H Segal, Bruno Bockorny, Justin C. Moser, Sunil Sharma, Jaymin Patel, Wei Wu, Dhan Chand, Katherine Rosenthal, Gabriel Mednick, Chloé Delépine, Tyler J. Curiel, Justin Stebbing, Heinz‐Josef Lenz, Steven O’Day, Anthony B. El-Khoueiry

    Published 2024
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC

    Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC by Scott Antonia, Ani Sarkis Balmanoukian, Julie R. Brahmer, Sai‐Hong Ignatius Ou, Matthew D. Hellmann, Sang-We Kim, Myung‐Ju Ahn, Dong‐Wan Kim, Martin Gutierrez, Stephen V. Liu, Patrick Schöffski, Dirk Jäger, Rahima Jamal, Guy Jérusalem, Jose Lutzky, John Nemunaitis, Luana Calabrò, Jared Weiss, Shirish M. Gadgeel, Jaishree Bhosle, Paolo A. Ascierto, Marlon C. Rebelatto, Rajesh Narwal, Meina Liang, Feng Xiao, Joyce Antal, Shaad E. Abdullah, Natasha Angra, Ashok Gupta, Samir N. Khleif, Neil H. Segal

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

    Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicent... by Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, Michiel S. van der Heijden, Arjun Vasant Balar, Andrea Necchi, Nancy A. Dawson, Peter H. O’Donnell, Ani Sarkis Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta Retz, Petros Grivas, Richard W. Joseph, Matthew D. Galsky, Mark T. Fleming, Daniel P. Petrylak, Jose Luis Pérez‐Gracia, Howard A. Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean F. Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M. Frampton, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Gregg Fine, Robert Dreicer

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: